Side-by-side IPO readiness, funding history, and valuation comparison. Data sourced by TechStackIPO.
Scores, valuations, and signals for Canva, Nimbus Therapeutics, and 370+ companies. 5-min read every Tuesday.
Canva is the world's leading design platform with 250M+ users — valued at $48B with $770M raised. Track IPO timeline, funding rounds, and readiness score.
| Industry | Design & Creative |
| Stage | Pre-IPO |
| IPO Status | Private |
| Valuation | $42B |
| Total Funding | $770M |
| Headquarters | Sydney, Australia |
Nimbus Therapeutics uses structure-based drug design and computational tools to develop precision medicines for challenging targets including NASH, oncology, and immunology. Valued at $2B with $500M raised, Nimbus has multiple clinical-stage programs and partnerships with Takeda and Eli Lilly. Major healthtech IPO candidate as computational drug design matures into commercial medicine.
| Industry | Biotechnology |
| Stage | Late Stage Private |
| IPO Status | Private |
| Valuation | $3.8B |
| Total Funding | $987M |
| Headquarters | Cambridge, MA |
Complete funding history, cap table, S-1 analysis, and investor breakdown for any company. Instant PDF download.
Or buy any single company report for $19
Canva is valued at $42B. Nimbus Therapeutics is valued at $3.8B. Both figures are based on the most recent funding rounds tracked by TechStackIPO.
Canva reported 4000000000 revenue in 2025. Nimbus Therapeutics's revenue is not publicly disclosed. Revenue figures are sourced from TechStackIPO's company database and updated as new data becomes available.
Canva filed an S-1 in November 2025 and is actively in the IPO pipeline. Nimbus Therapeutics is currently private. Track both companies on TechStackIPO for S-1 filings, roadshow announcements, and IPO date updates.
Canva has raised $770M. Nimbus Therapeutics has raised $987M.
Canva operates in Design & Creative, while Nimbus Therapeutics operates in Biotechnology.
Canva is a Design & Creative company valued at $42B with $770M raised. Nimbus Therapeutics is a Biotechnology company valued at $3.8B with $987M raised. See TechStackIPO's full side-by-side comparison for IPO readiness scores, funding timelines, and investor access options.
Accredited investors can access pre-IPO shares in Canva and Nimbus Therapeutics through secondary market platforms, pre-IPO funds, and broker-dealer platforms that facilitate private company transactions. TechStackIPO's marketplace section tracks available access options for both companies. Pre-IPO investments carry higher risk and limited liquidity.